These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18276066)

  • 1. Editorial comment on: combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
    Oudard S
    Eur Urol; 2008 Nov; 54(5):1094-6. PubMed ID: 18276066
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
    Di Lorenzo G; Figg WD; Fossa SD; Mirone V; Autorino R; Longo N; Imbimbo C; Perdonà S; Giordano A; Giuliano M; Labianca R; De Placido S
    Eur Urol; 2008 Nov; 54(5):1089-94. PubMed ID: 18276061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of docetaxel resistance with bevacizumab and thalidomide.
    Ning YM; Figg WD; Dahut WL
    Clin Genitourin Cancer; 2009 Aug; 7(2):E37-8. PubMed ID: 19692321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role of inhibiting the vascular endothelial growth factor pathway in advanced prostate cancer.
    Clin Prostate Cancer; 2005 Sep; 4(2):80-2. PubMed ID: 16197606
    [No Abstract]   [Full Text] [Related]  

  • 6. Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts.
    Hung H
    Mol Cancer Ther; 2007 Aug; 6(8):2149-57. PubMed ID: 17699714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
    Ohlmann CH; Markert E; Gerharz M; Pfister D; Dienes HP; Engelmann U; Heidenreich A
    Urologe A; 2008 Sep; 47(9):1218-23. PubMed ID: 18679646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab for advanced breast cancer.
    Goldfarb SB; Traina TA; Dickler MN
    Womens Health (Lond); 2010 Jan; 6(1):17-25. PubMed ID: 20001867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
    Ortholan C; Durivault J; Hannoun-Levi JM; Guyot M; Bourcier C; Ambrosetti D; Safe S; Pagès G
    Eur J Cancer; 2010 Nov; 46(16):3022-36. PubMed ID: 20729074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [AUO study in hormone-refractory prostate cancer. Phase III study on treatment of hormone-refractory prostate cancer (HRPC) with docetaxel: continuous treatment vs. intermittent repetition of treatment after renewed progression--PRINCE].
    Rexer H
    Urologe A; 2006 Jul; 45(7):872. PubMed ID: 16791626
    [No Abstract]   [Full Text] [Related]  

  • 11. [Efficacy of standard docetaxel and metronomic cyclophosphamide chemotherapy in patients with hormone-resistant prostate cancer: comparative analysis].
    Vorob'ev NA; Nosov AK; Vorob'ev AV; Moiseenko BM
    Vopr Onkol; 2011; 57(6):753-8. PubMed ID: 22416393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic strategies in development for prostate cancer.
    Harzstark AL; Ryan CJ
    Expert Opin Investig Drugs; 2008 Jan; 17(1):13-22. PubMed ID: 18095915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel angiogenesis inhibitors in nonsmall cell lung cancer.
    Reinmuth N; Heigener D; Reck M
    Curr Opin Oncol; 2015 Mar; 27(2):79-86. PubMed ID: 25602682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
    Soria JC
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S35-6. PubMed ID: 16719155
    [No Abstract]   [Full Text] [Related]  

  • 17. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.
    Legrier ME; Oudard S; Judde JG; Guyader C; de Pinieux G; Boyé K; de Cremoux P; Dutrillaux B; Poupon MF
    Br J Cancer; 2007 Jan; 96(2):269-76. PubMed ID: 17211467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches in hormone refractory prostate cancer.
    Sonpavde G; Hutson TE
    Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.
    Tyagi P
    Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.